Epilepsy is one of the most common neurological chronic disorders, with an estimated
prevalence of 0. 5–1%. Currently, treatment options for epilepsy are predominantly based on …

More than 150 years after bromide was introduced as the first antiepileptic drug, adverse
effects remain a leading cause of treatment failure and a major determinant of impaired …

Objective: The long-term efficacy and safety of responsive direct neurostimulation was
assessed in adults with medically refractory partial onset seizures. Methods: All participants …

В руководстве представлены результаты 60-летней работы автора в области детской
и взрослой неврологии и эпилептологии. Впервые эпилептология представлена в …

Objective To demonstrate the safety and effectiveness of responsive stimulation at the
seizure focus as an adjunctive therapy to reduce the frequency of seizures in adults with …

Objective During the development of cenobamate, an antiseizure medication (ASM) for focal
seizures, three cases of drug reaction with eosinophilia and systemic symptoms (DRESS) …

Objective To evaluate the efficacy and safety of adjunctive cenobamate 200 mg/d in patients
with uncontrolled focal (partial-onset) seizures despite treatment with 1 to 3 antiepileptic …

Background More than a third of patients with epilepsy are treatment resistant, and thus new,
more effective therapies to achieve seizure freedom are needed. Cenobamate (YKP3089) …

Status epilepticus (SE) represents the most severe form of epilepsy. It is one of the most
common neurologic emergencies, with an incidence of up to 61 per 100,000 per year and …

The RNS® System is the first commercially available device to provide closed-loop
responsive brain stimulation. The system includes a cranially implanted neurostimulator that …